U.S. Gives AstraZeneca $1.2 Billion to Manufacture COVID-19 Vaccine

May 22, 2020

The U.S. government is giving AstraZeneca up to $1.2 billion to manufacture a COVID-19 vaccine it is developing with the University of Oxford.

The UK-based drugmaker is partnering with HHS to make at least 300 million doses of the vaccine AZD1222. The funding will go toward development, production and delivery of at least 300 million doses.

The first doses are expected to be delivered as early as October.

Pharmaceuticals Regulatory Affairs

Novavax Acquires Praha Vaccines to Expand COVID-19 Manufacturing Capacity

U.S. Gives AstraZeneca $1.2 Billion to Manufacture COVID-19 Vaccine

Upcoming Events

Implementing Clinical and Performance Evaluation Reports for Your Medical Device: Best Practices for Getting them Right

Biosimilars on the Rise: The Latest on FDA’s Guidelines and Guidances

Pharmaceutical Social Media Advertising: Expand Your Reach and Prevent Regulatory Mistake

Medical Devices and Digital Health After COVID-19: Implications for the Industry and Your Business

Medical Device Corrections and Removals, Recalls and Closures: Best Practices for Call Center Operations and Notice

Dealing with FCPA and Other Investigations Under the New Normal

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

Novavax Initiates Human Trial of COVID-19 Vaccine in Australia

4DMedical’s Lung-Imaging Technology Cleared

Novavax Acquires Praha Vaccines to Expand COVID-19 Manufacturing Capacity

Siemens Healthineers’ Coronavirus Antibody Test CE Marked

The Revised ICH E8: A Guide to New Clinical Trial Requirements

U.S. Gives AstraZeneca $1.2 Billion to Manufacture COVID-19 Vaccine

Related Events

The Revised ICH E8: A Guide to New Clinical Trial Requirements